
Advertisement
Advertisement
Trending on Rheumatology Live
1
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA Study
2
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head
3
OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhD
4
Nipocalimab Demonstrates Proof of Concept for FcRn Blockade for SLE
5


























































